Pharma & Biotech Global Week in Review 30 Nov 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

EU: CJEU guidance on Article 3(a) SPC Regulation: What does “specified in the wording of the claims” mean?: Medeva v. Comptroller General of Patents (Kluwer Patent Blog) (EPLAW) (The SPC Blog)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

IP, trade and public health leaders turn a page in history together (IP Watch)

Cuba: Some news from Cuba: biotechnology and medicines – an international conference, cooperation between China and Cuba, and vaccine against lung cancer (IP tango)

EU: CJEU clarifies exhaustion in plant varieties rights: Greenstar-Kanzi Europe NV v Jean Hustin, Jo (IPR Helpdesk)

EU: CJEU guidance on Article 3(a) SPC Regulation: What does “specified in the wording of the claims” mean?: Medeva v. Comptroller General of Patents (Kluwer Patent Blog) (EPLAW) (The SPC Blog)

EU: CJEU delivers judgment in Georgetown University v. Comptroller General of Patents / SPC (EPLAW) (The SPC Blog)

Poland: drugs, trade marks and Internet domains (Class 46)

US: ICD2 2012 Conference – Fostering innovation and translational research in support of public health and economic growth (FDA Law Blog)

US: Justice Kennedy and the Affordable Health Care Act (IPBiz)

US: Rep. Burgess introduces Genetic Diagnostic Testing Bill (Patent Docs)

US: Federal gov help for small biotech filing foreign patent applications? (IPBiz)

US: Yeda Research files for review and correction of patent term adjustment calculation (Patent Docs)

 

Products

Actos (Pioglitazone) – US: Takeda files patent infringement complaint against Hetero Drugs in response to Para IV certification (Patent Docs)

Angiomax (Bivalirudin) – US: Medicines Co files patent infringement suits against Sun Pharma in New Jersey and Michigan following Para IV certification filing (Patent Docs)

Atorvastatin – Spain: Supreme court confirms that “bolar provision” does not apply retrospectively (Kluwer Patent Blog)

Atorvastatin – US: Pfizer settles Lipitor patent suits with Aurobindo, Kremers (Patent Docs)

Cefperazone sodium and Sulbactam sodium – China: Biggest medicine patent licensing case closed Wei Er Man obtained 4.7 million yuan (China Blawg)

Cotareg (Valsartan, HCTZ) – Italy: Court of Rome applies Medeva, suspends provisional relief (The SPC Blog)

Exelon (Rivastigmine) – US: Novartis files patent infringement suit against Watson in response to Para IV certificaton (Patent Docs)

Fentora (Fentanyl) – US: Cephalon files patent infringement complaint against Impax following Para IV certification (Patent Docs)

Focalin XR(Dexmethylphenidate) – US: Alkermes Pharma Ireland and Celgene file separate patent infringement suits against Par Pharmaceuticals in response to Para IV certification (Patent Docs)

Generess Fe (Norethindrone, Ethinyl estradiol) – US: Warner Chilcott files patent infringement complaint against Mylan following Para IV challenge (Patent Docs)

Indazole – Israel: How many lawyers does it take to cross examine a witness?: Takeda Chemical Industries vs. Rafa Laboratories (The IP Factor)

Leflunomide – Australia: Justice Jagot rejects ‘manifestly absurd and unreasonable’ construction of new copyright exemption for PI documents: Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3) (IP Whiteboard)

Levitra – US: Teva and Bayer settle dispute over Levitra patents (Patent Docs)

Lumigan (Bimatoprost) – US: Allergan files patent infringement complaint against Lupin in response to Para IV challenge (Patent Docs)

Nexavar (Sorafenib) – India: Delhi High Court dismissed Bayer’s petition against publication of Natco’s CL application by Controller General of Patents (Spicy IP)

OxyContin (Oxycodone) – US: Purdue Pharma files patent infringement complaint against Amneal Pharmaceuticals following Para IV certification (Patent Docs)

Roundup Ready soybeans – US: What’s blue, black, green and yellow and can cost a fortune? Monsanto v Bowman (IPKat)

Seroquel (Quetiapine) – Bulgaria: Supreme Administrative Court overrules Patent Office denying AstraZeneca’s application for SPC (Kluwer Patent Blog)

Taxotere (Docetaxel) – US: Aventis files patent infringement suit against Strides in response to Para IV certification (Patent Docs)

Vivelle-Dot (Estradiol) – US: Mylan and Novartis settle patent suit over Vivelle-Dot (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: